0 item(s)
View cart
You have no items in your shopping cart.
13
Apr
Next-Generation cfDNA Isolation: Precision Meets Scalability with Biofargo
In the rapidly evolving landscape of liquid biopsy and clinical oncology, the ability to isolate ultra-low abundance circulating cell-free DNA (cfDNA) is the cornerstone of successful diagnostic outcomes.
In the rapidly evolving landscape of liquid biopsy and clinical oncology, the ability to isolate ultra-low abundance circulating cell-free DNA (cfDNA) is the cornerstone of successful diagnostic outcomes. For research teams and diagnostic developers, the challenge is two-fold: achieving high-fidelity recovery from complex matrices and maintaining consistency across high-throughput workflows.
Understanding the Clinical Value of Circulating Cell-Free DNA
Circulating cell-free DNA consists of highly fragmented extracellular DNA molecules freely circulating in bodily fluids such as plasma, serum, and urine. Released primarily through cellular apoptosis, necrosis, active secretion, and NETosis, these target fragments typically range from 160 to 170 base pairs in length.
In clinical oncology, cfDNA derived from tumor cells carries critical genetic and epigenetic alterations identical to the primary tumor. This makes cfDNA an invaluable biomarker for non-invasive liquid biopsies, enabling early cancer detection, real-time monitoring of treatment efficacy, and tracking of minimal residual disease.
Beyond oncology, cfDNA has emerged as a transformative diagnostic tool across multiple medical disciplines. It is now widely utilized in Non-Invasive Prenatal Testing, transplant monitoring, and autoimmune disease management.
However, due to its extremely low abundance and interference from high-molecular-weight genomic DNA, achieving high-yield, high-purity extraction remains a major technical challenge.
At Biofargo, we have engineered the ReadiMag™ cfDNA Isolation series to bridge the gap between laboratory flexibility and industrial efficiency, solving this exact bottleneck.
1. The Versatility Benchmark: ReadiMag™ cfDNA Isolation Kit (Bulk Format)
For laboratories managing diverse sample inputs, the Biofargo ReadiMag™ cfDNA Isolation Kit (SKU 180248) offers unparalleled protocol flexibility. This bulk-reagent format supports a wide sample range from 500 μL up to 10 mL.
Key Technical Advantages:
- Multi-Matrix Compatibility: Validated for plasma, serum, and urine samples.
- Precision Elution: Supports 15–50 μL elution for maximum cfDNA concentration.
- Open System Integration: Compatible with KingFisher Flex 715, ANDiS 360, and Auto-Pure 24 platforms.
This kit is ideal for translational research requiring protocol optimization and high sensitivity.
2. The Automation Standard: Pre-filled ReadiMag™ cfDNA Isolation Kit
For high-throughput and standardized workflows, the Biofargo ReadiMag™ cfDNA Isolation Kit (SKU 180395) provides a fully automated solution with pre-filled 24-well plates.
Key Advantages:
- Rapid Processing: Complete workflow in ~50 minutes.
- Minimized Human Error: Pre-filled plates eliminate manual handling.
- Scalable Input: Supports 4 mL per plate and up to 8 mL with dual plates.
Reliable Science
Both Biofargo ReadiMag™ systems utilize proprietary magnetic bead technology to ensure accurate cfDNA fragment size recovery and high purity.
Whether for pilot research or large-scale clinical workflows, these kits deliver reproducible and high-quality DNA for downstream applications such as NGS and digital PCR.
Explore the Series
Biofargo team
